433 related articles for article (PubMed ID: 21436619)
1. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
[TBL] [Abstract][Full Text] [Related]
2. Targeting Plk1 in cutaneous T-cell lymphomas (CTCLs).
Liu XS; Liu X
Cell Cycle; 2011 May; 10(10):1523. PubMed ID: 21478668
[No Abstract] [Full Text] [Related]
3. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.
Lansing TJ; McConnell RT; Duckett DR; Spehar GM; Knick VB; Hassler DF; Noro N; Furuta M; Emmitte KA; Gilmer TM; Mook RA; Cheung M
Mol Cancer Ther; 2007 Feb; 6(2):450-9. PubMed ID: 17267659
[TBL] [Abstract][Full Text] [Related]
4. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.
Ikezoe T; Yang J; Nishioka C; Takezaki Y; Tasaka T; Togitani K; Koeffler HP; Yokoyama A
Leukemia; 2009 Sep; 23(9):1564-76. PubMed ID: 19421227
[TBL] [Abstract][Full Text] [Related]
5. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
6. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
Gilmartin AG; Bleam MR; Richter MC; Erskine SG; Kruger RG; Madden L; Hassler DF; Smith GK; Gontarek RR; Courtney MP; Sutton D; Diamond MA; Jackson JR; Laquerre SG
Cancer Res; 2009 Sep; 69(17):6969-77. PubMed ID: 19690138
[TBL] [Abstract][Full Text] [Related]
7. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
Pajtler KW; Sadowski N; Ackermann S; Althoff K; Schönbeck K; Batzke K; Schäfers S; Odersky A; Heukamp L; Astrahantseff K; Künkele A; Deubzer HE; Schramm A; Sprüssel A; Thor T; Lindner S; Eggert A; Fischer M; Schulte JH
Oncotarget; 2017 Jan; 8(4):6730-6741. PubMed ID: 28036269
[TBL] [Abstract][Full Text] [Related]
8. A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt's lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis.
Ergul M; Bakar-Ates F
Chem Biol Interact; 2020 Dec; 332():109288. PubMed ID: 33075310
[TBL] [Abstract][Full Text] [Related]
9. Targeting expression or function of Plk1 in CTCL, that is a question.
Wu S
Cell Cycle; 2011 May; 10(10):1526. PubMed ID: 21478673
[No Abstract] [Full Text] [Related]
10. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
11. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
Shin SB; Woo SU; Yim H
J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel.
Chou YS; Yen CC; Chen WM; Lin YC; Wen YS; Ke WT; Wang JY; Liu CY; Yang MH; Chen TH; Liu CL
Int J Oncol; 2016 Mar; 48(3):1187-94. PubMed ID: 26794530
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
[TBL] [Abstract][Full Text] [Related]
14. Effect of PLK1 inhibition on cisplatin-resistant gastric cancer cells.
Chen Z; Chai Y; Zhao T; Li P; Zhao L; He F; Lang Y; Qin J; Ju H
J Cell Physiol; 2019 May; 234(5):5904-5914. PubMed ID: 30488440
[TBL] [Abstract][Full Text] [Related]
15. Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus.
Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Menendez JA
Cell Cycle; 2011 Apr; 10(8):1295-302. PubMed ID: 21474997
[TBL] [Abstract][Full Text] [Related]
16. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
[TBL] [Abstract][Full Text] [Related]
17. Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001.
Lan R; Lin G; Yin F; Xu J; Zhang X; Wang J; Wang Y; Gong J; Ding YH; Yang Z; Lu F; Zhang H
Lab Invest; 2012 Oct; 92(10):1503-14. PubMed ID: 22890557
[TBL] [Abstract][Full Text] [Related]
18. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
[TBL] [Abstract][Full Text] [Related]
19. The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.
Russo MA; Kang KS; Di Cristofano A
Thyroid; 2013 Oct; 23(10):1284-93. PubMed ID: 23509868
[TBL] [Abstract][Full Text] [Related]
20. RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients.
Kolosenko I; Goroshchuk O; Vidarsdottir L; Björklund AC; Dowdy SF; Palm-Apergi C
FASEB J; 2021 May; 35(5):e21476. PubMed ID: 33788972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]